This is a Phase I, Open label First in Human Study in adult patients with relapsed advanced malignancies.~The study will have two parts. Dose escalation part and Dose expansion part
This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies.~The study will have two parts: a Dose Escalation Part and Dose Expansion Part.